FDA warns ProDx Health that its HIV sample self-collection kits are sold without marketing authorization.
What happened
FDA reviewed ProDx Health's website in February 2026 and the firm's February 3, 2026 response to earlier FDA correspondence. FDA found the firm offers HIV serological diagnostic sample self-collection kits for delivery to individuals to self-collect samples and ship them to labs for HIV testing without FDA's approval for the device (a PMA) or approval to study it (an IDE). FDA also said the firm did not provide the required pre-sale notification to FDA (a 510(k)).
What FDA found
The HIV sample self-collection kits are adulterated because they have no approved premarket approval application or approved investigational device exemption.
FD&C Act section 501(f)(1)(B), 21 U.S.C. 351(f)(1)(B); section 515(a), 21 U.S.C. 360e(a); section 520(g), 21 U.S.C. 360j(g)The kits are misbranded because ProDx Health did not notify FDA before introducing the device into commercial distribution.
FD&C Act section 502(o), 21 U.S.C. 352(o); section 510(k), 21 U.S.C. 360(k)
What FDA wants
FDA asks ProDx Health to immediately stop any activities that cause the kits to be misbranded or adulterated. Within 15 working days of receipt, the firm must write to FDA with the steps taken to correct the violations, prevent recurrence, and related documentation; if it cannot finish, it must explain the delay and give a completion date.
Who should pay attention
- makers of at-home sample collection kits
- HIV test developers and labs receiving self-collected samples
- companies selling diagnostic devices without FDA marketing authorization
This is a summary. Read the original letter on fda.gov.